Enveric Biosciences Inc
(ENVB)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,503 | 6,356 | 2,288 | 4,267 | 7,081 |
| TOTAL | $5,520 | $8,229 | $3,582 | $5,827 | $8,900 |
| Non-Current Assets | |||||
| PPE Net | 405 | 452 | 507 | 539 | 595 |
| Intangibles | 127 | 169 | 211 | 253 | 295 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 10 |
| TOTAL | $532 | $621 | $718 | $792 | $900 |
| Total Assets | $6,052 | $8,850 | $4,300 | $6,619 | $9,800 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 460 | 1,853 | 1,219 | 1,098 | 1,235 |
| Other current liabilities | 9 | 28 | 49 | 1,552 | 2,182 |
| TOTAL | $645 | $2,368 | $2,344 | $4,184 | $4,926 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $645 | $2,368 | $2,344 | $4,184 | $4,926 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 50 | 43 | 41 | 13 | 12 |
| Common Shares | 79 | 73 | 2 | 22 | 21 |
| Retained earnings | -100,836 | -98,956 | -96,500 | -93,064 | -90,241 |
| Other shareholders' equity | -567 | -552 | -2,387 | -536 | -546 |
| TOTAL | $5,406 | $6,482 | $1,956 | $2,436 | $4,875 |
| Total Liabilities And Equity | $6,052 | $8,850 | $4,300 | $6,619 | $9,800 |